Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 15;24(11):1207-1212.
doi: 10.7499/j.issn.1008-8830.2205011.

[Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity]

[Article in Chinese]
Qing-Fei Hao  1 , Jing Chen  1 , Peng Ruan  1 , Gao-Pan Li  1 , Jing Zhang  1 , Hao-Ming Chen  1 , Hong-Xiang Guo  1 , Xiao-Juan Sun  1 , Xiu-Yong Cheng  1
Affiliations

[Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity]

[Article in Chinese]
Qing-Fei Hao et al. Zhongguo Dang Dai Er Ke Za Zhi. .

Abstract
in English, Chinese

Objectives: To investigate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in the treatment of retinopathy of prematurity (ROP) and the risk factors for recurrence.

Methods: A retrospective analysis was performed on the medical data of 159 infants with ROP who were born in the First Affiliated Hospital of Zhengzhou University and underwent anti-VEGF treatment from January 2016 to December 2021. According to the presence or absence of recurrence within the follow-up period after initial anti-VEGF treatment, they were divided into a recurrence group with 24 infants and a non-recurrence group with 135 infants. The medical data were compared between the two groups, and a multivariate logistic regression analysis was used to investigate the risk factors for the recurrence of ROP after anti-VEGF treatment.

Results: After one-time anti-VEGF treatment, all 159 infants showed regression of plus disease. Recurrence was observed in 24 infants (15.1%) after anti-VEGF treatment, with a mean interval of (8.4±2.6) weeks from treatment to recurrence. The multivariate logistic regression analysis showed that preoperative fundus hemorrhage and prolonged total oxygen supply time were risk factors for the recurrence of ROP (P<0.05), while gestational hypertension was a protective factor (P<0.05).

Conclusions: Intravitreal anti-VEGF injection is effective for ROP. Preoperative fundus hemorrhage and long duration of oxygen therapy may increase the risk of ROP recurrence, and further studies are needed to investigate the influence of gestational hypertension on the recurrence of ROP.

目的: 探讨玻璃体腔内注射抗血管内皮生长因子（vascular endothelial growth factor，VEGF）治疗早产儿视网膜病（retinopathy of prematurity，ROP）的效果及复发的危险因素。方法: 回顾性收集2016年1月—2021年12月在郑州大学第一附属医院出生行抗VEGF治疗的ROP患儿159例的临床资料，根据首次抗VEGF治疗后随访周期内ROP复发与否分为复发组（24例）和非复发组（135例），比较分析2组临床资料，采用多因素logistic回归分析探讨抗VEGF治疗ROP复发的危险因素。结果: 经单次抗VEGF治疗后，所有159例患儿均显示附加病变消退。24例（15.1%）抗VEGF治疗后复发，复发平均时间为治疗后（8.4±2.6）周。多因素logistic回归分析显示，术前眼底出血、总用氧时间较长是ROP复发的危险因素（P<0.05），而妊娠高血压是保护因素（P<0.05）。结论: 玻璃体腔内注射抗VEGF治疗ROP是有效的。术前眼底出血和氧疗时间较长可增加ROP复发的风险，而对于妊娠高血压对ROP复发的影响，还需进一步研究证实。.

Keywords: Anti-vascular endothelial growth factor; Preterm infant; Recurrence; Retinopathy of prematurity.

PubMed Disclaimer

Figures

图1
图1. 首次抗VEGF治疗后无复发生存曲线
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Blencowe H, Lawn JE, Vazquez T, et al. . Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010[J]. Pediatr Res, 2013, 74(Suppl 1): 35-49. DOI: 10.1038/pr.2013.205. - DOI - PMC - PubMed
    1. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity[J]. N Engl J Med, 2012, 367(26): 2515-2526. DOI: 10.1056/NEJMra1208129. - DOI - PMC - PubMed
    1. Palmer EA, Hardy RJ, Dobson V, et al. . 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity[J]. Arch Ophthalmol, 2005, 123(3): 311-318. DOI: 10.1001/archopht.123.3.311. - DOI - PubMed
    1. Travassos A, Teixeira S, Ferreira P, et al. . Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity[J]. Ophthalmic Surg Lasers Imaging, 2007, 38(3): 233-237. DOI: 10.3928/15428877-20070501-09. - DOI - PubMed
    1. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. . Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity[J]. N Engl J Med, 2011, 364(7): 603-615. DOI: 10.1056/NEJMoa1007374. - DOI - PMC - PubMed

Publication types